International Forum on Visceral Myopathy 2024: Advances in the Knowledge of the Disease
Researchers have synthesized new genetic and molecular insights into visceral smooth muscle disease, charting promising experimental directions for this currently untreatable condition.
The International Forum on Visceral Myopathy 2024 synthesized global advances in the understanding of VSCM genetics (ACTG2, MYH11), pathophysiology, and novel experimental treatments for this ultra-rare life-threatening condition with no current disease-modifying therapy. The consensus highlights key unmet needs and emerging research directions for gut smooth muscle disorders.
What the study was
- Study design
- Conference consensus summary / Review
- Population
- Patients with visceral myopathy (ACTG2/MYH11/FLNA mutations; CIPO/PIPO/MMIH syndrome)
- Category
- Other
- Maturity
- Exploratory
- Journal
- Neurogastroenterology and Motility
Why it surfaced
Ultra-rare condition (VSCM/CIPO/PIPO) with extreme unmet need; consensus from global expert group has practical value for rare disease surveillance; design quality 0 as conference summary/review, not primary research.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.